GLPG-3667 is under clinical development by Galapagos and currently in Phase I for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData, Phase I drugs for Plaque Psoriasis (Psoriasis Vulgaris) have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GLPG-3667’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GLPG-3667 overview
GLPG-3667 is under development for the treatment of inflammation and moderate to severe plaque psoriasis, dermatomyositis, psoriatic arthritis. The drug candidate is a small molecule. It is administered by oral route. It acts by targeting nonreceptor tyrosine protein kinase (TYK2).
The drug candidate was under development for the treatment of ulcerative colitis.
Galapagos overview
Galapagos is a biotechnology company that focuses on transforming patient outcomes through scientific innovation. It focuses on the development of small molecules and cell therapies targeting oncology and immunology. The company’s products include CAR-T therapies and biologics designed to address high unmet medical needs. Galapagos’ pipeline products include GLPG5101, GLPG5201, GLPG5301 and GLPG3667 for the indications of non-hodgkin’s lymphoma, chronic lymphocytic leukemia, multiple myeloma, systemic lupus erythematosus, dermatomyositis and other rare diseases. It serves patients and healthcare providers by offering treatments for various cancers and autoimmune disorders. The company operates in the US, the Netherlands, France, Switzerland, and the UK. Galapagos is headquartered in Mechelen, Belgium.
For a complete picture of GLPG-3667’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
